Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group
| Autor: | P Drouin, K Swenerton, G O'Connell, J A Carmichael, Gd Maclean, Gavin Stuart, M. Roy, Garry V. Krepart, R Stanimir, J.F. Jeffrey |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Cancer Research
medicine.medical_specialty Chemotherapy Performance status Cyclophosphamide business.industry medicine.medical_treatment medicine.disease Gastroenterology Carboplatin Surgery law.invention Clinical trial chemistry.chemical_compound Regimen Oncology Randomized controlled trial chemistry law Internal medicine medicine business Progressive disease medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 10:718-726 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1992.10.5.718 |
| Popis: | PURPOSE Given the potential for improved tolerance, a trial was initiated to compare the toxicity and efficacy of a standard regimen of cisplatin-cyclophosphamide (75 mg/m2 and 600 mg/m2, respectively) with an experimental regimen of carboplatin-cyclophosphamide (300 mg/m2 and 600 mg/m2, respectively) in women with postoperative macroscopic residual ovarian cancer. PATIENTS AND METHODS Between 1985 and 1989, 447 (417 eligible) patients were randomized. Treatment arms were well balanced; most patients had stage III (82%), grade 3 (54%) tumors with bulky residual (greater than 2 cm in 59%), and good performance status (Eastern Cooperative Oncology Group [ECOG] 0 or 1, 77%). Response was assessed after six 4-week cycles. RESULTS The treatments were equally deliverable, with 76% of patients completing their allocated regimen. The reported reasons for failure to complete treatment differed; toxicity/refusal predominated on the cisplatin arm, and progressive disease predominated on the carboplatin arm (P = .0092). Cisplatin-treated patients were more likely to develop neuropathy and nephropathy, and carboplatin patients experienced myelosuppression, particularly thrombocytopenia. Efficacy was similar, with no significant differences for the cisplatin and carboplatin arms in clinical response rate (57% v 59% in those with measurable disease), pathologic response rate (52% v 54% in those suitable for relaparotomy), time to progression (median, 56 v 58 weeks), or overall survival (median, 100 weeks v 110 weeks). Time to progression and survival were predicted by residual disease size, performance status, and treatment center (with those treated at centers that accrued more patients doing better). CONCLUSION Neither regimen is optimal in that relapse remains the norm. It may be inappropriate to expect that any single regimen can be an effective therapy for all patients with advanced ovarian cancer. Both cisplatin and carboplatin are likely to have a role in future treatment strategies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|